Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib
Year: 2025
Type: article
Abstract: The Meet-URO score provided a more accurate prognostication than the international metastatic RCC database consortium (IMDC) risk group classification for patients with metastatic renal cell carcinoma (mRCC) by incorporating the pretreatment neutrophil-to-lymphocyte ratio (NLR) and the presence of bone metastases in different settings of the disease. To additionally validate the Meet-URO score on overall survival (OS) in a cohort of mRCC patients treated with first-line pembrolizumab plus axitinib, a post hoc analysis of the observational prospective ProPAXI study was conducted. Progression-free survival (PFS) was also considered. Harrell’s C-index was used to compare the discriminative ability on OS and PFS. Overall, the ProPAXI study included 170 patients. Both the five- and the three-risk group Meet-URO score were evaluated to account for the small sample size. The five Meet-URO risk group score showed a mOS of 27.1 months (p = 0.064) and 10.3 (p = 0.014) months for group 4 and group 5, respectively, while it was not reached for the other groups (p < 0.01). Although a worsening of PFS was observed with increasing the risk group, these differences were not statistically significant (p =0.19). Similar results were observed fot the three-risk group Meet-URO score. Both five and the three Meet-URO risk groups showed a better C-index for OS (0.69 and 0.66, respectively) compared to IMDC (0.62) and for PFS (0.60 and 0.59, respectively) compared to IMDC (0.56). These findings suggest that the Meet-URO score may provide more accurate prognostic stratification than IMDC alone in mRCC patients treated with first-line pembrolizumab and axitinib.
Source: Journal of Kidney Cancer and VHL
Authors: Giulia Airò, Annalisa Guida, Alessio Gili, Alessio Signori, Sara Elena Rebuzzi, Marco Maruzzo, Eleonora Lai, Francesco Pierantoni, Davide Bimbatti, Umberto Basso, Alessandra Damassi, Fabio Calabrò, Linda Cerbone, Claudia Caserta, Grazia Sirgiovanni, Debora Serafin, Orazio Caffo, Sarah Scagliarini, Sergio Bracarda, Sebastiano Buti
Institutions: University of Parma, Azienda Ospedaliera S.Maria, Link Campus University, University of Genoa, Ospedale San Paolo, Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori Regina Elena, Azienda Ospedaliera San Camillo-Forlanini, Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Ospedale Antonio Cardarelli
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4415315447